The Company Headquartered in the heart of Silicon Valley, Sunnyvale, Calif., AeroGen specializes in pulmonary drug delivery for treating respiratory diseases. Similar to most biotech companies, AeroGen is still far from turning into a profitable business, although it has been in operation for nine years. Competition, Backing AeroGen ranks a distant third in its major business. It is also in early-stage trials of its insulin products and does not have a contract to obtain commercial quantities of hormone. To better position itself in an industry dominated by larger players, AeroGen strives to cooperate with big drug companies willing to provide a more versatile range of services.
Quantity is no guarantee for quality, and the third-quarter biotech stock performance proved it.
But while money-raising activity grew with a rapid pace, biotech stock performance remained modest. All Rights Reserved.